Dr. Yessica R. Sachdeva, M.D.
Internal Medicine (Internal Medicine Physician)
616 E Southern Ave, Suite 103
Mesa, AZ 85204
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 105
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
AZ license 45975 -
Hospitalist Physician
AZ license 45975 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Institute for Liver Health LLC (20 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 105
- Services billed
- 357
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Ultrasound scan of organ tissue for measuring elasticity | 73 | 58 |
| Established patient office or other outpatient visit, 30-39 minutes | 69 | 42 |
| Insertion of needle into vein for collection of blood sample | 53 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 33 | 27 |
| New patient office or other outpatient visit, 45-59 minutes | 30 | 30 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in Mesa, AZ | 44 |
| Ursodiol Other prescribers in Mesa, AZ | 32 |
| Lactulose Other prescribers in Mesa, AZ | 28 |
| Potassium Chloride Other prescribers in Mesa, AZ | 28 |
| Epclusa (sofosbuvir/velpatasvir) | 15 |
| Rezdiffra (resmetirom) | 12 |
| Ozempic (semaglutide) Other prescribers in Mesa, AZ | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 29 payments worth $681 in total to this clinician.
| Madrigal Pharmaceuticals | $228 |
|---|---|
| Gilead Sciences, Inc. | $173 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.26 |
| AbbVie Inc. | $47.38 |
| Intercept Pharmaceuticals, Inc. | $36.80 |
| AstraZeneca Pharmaceuticals LP | $34.39 |
| Ipsen Biopharmaceuticals, Inc | $33.84 |
| Novo Nordisk Inc | $25.89 |
| Food and Beverage | $681 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 22 industry-funded studies in 2025, from 7 companies. The companies reported $1,588,681 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity
AstraZeneca Pharmaceuticals LP - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT06603571 - Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
Eli Lilly and Company · Status unknown · NCT02968303 - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523 - A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fib…
AstraZeneca Pharmaceuticals LP - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company · Active, not recruiting · NCT05869903 - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.